| Patents for A61P 35 - Antineoplastic agents (221,099) |
|---|
| 04/22/2010 | US20100098665 Method of cancer treatment |
| 04/22/2010 | US20100098659 Compositions and methods for treating matrix metalloproteinase 9 (mmp9)-mediated conditions |
| 04/22/2010 | US20100098654 Treatment of neuroblastoma with multi-arm polymeric conjugates of 7-ethyl-10-hydroxycamptothecin |
| 04/22/2010 | US20100098653 Antioxidant polymers containing [1,2]-dithiolane moieties and uses thereof |
| 04/22/2010 | US20100098635 Modular antigen transporter molecules (mat molecules) for modulating immune reactions, associated constructs, methods and uses |
| 04/22/2010 | US20100098633 Selective seprase inhibitors |
| 04/22/2010 | US20100098632 Hydroxyapatite particles |
| 04/22/2010 | US20100098628 Proteins |
| 04/22/2010 | US20100098627 Proteins |
| 04/22/2010 | US20100098626 Protein |
| 04/22/2010 | US20100098625 Icbp90 polypeptide and its fragments and polynucleotides coding for said polypeptides and applications for diagnosing and treating cancer |
| 04/22/2010 | US20100098624 Method for using cdo antagonists to modulate hedgehog signaling |
| 04/22/2010 | CA2743828A1 Fas/fasl or other death receptor targeted methods and compositions for killing tumor cells |
| 04/22/2010 | CA2741069A1 Inhibitors of mitosis for increasing apoptosis in therapy |
| 04/22/2010 | CA2741065A1 Muc-1 cytoplasmic domain peptides as inhibitors of cancer |
| 04/22/2010 | CA2740885A1 Fused ring heteroaryl kinase inhibitors |
| 04/22/2010 | CA2740779A1 Tumor vaccine |
| 04/22/2010 | CA2740484A1 S1p receptors modulators and their use thereof |
| 04/22/2010 | CA2740471A1 Morpholinopurine derivatives |
| 04/22/2010 | CA2740317A1 Etoposide and doxorubicin conjugates for drug delivery |
| 04/22/2010 | CA2740134A1 Formulations targeting igfbp7 for diagnosis and therapy of cancer |
| 04/22/2010 | CA2739901A1 S1p receptors modulators |
| 04/22/2010 | CA2739545A1 Method of determining a phosphorus binder dosage for a dialysis patient |
| 04/22/2010 | CA2739488A1 Fused heteroaryl diamide compounds useful as mmp-13 inhibitors |
| 04/22/2010 | CA2739148A1 Tetra-aza-heterocycles as phosphatidylinositol-3-kinases (pi3-kinases) inhibitor |
| 04/22/2010 | CA2738609A1 Piperidine compounds, pharmaceutical composition comprising the same and its use |
| 04/22/2010 | CA2737855A1 Di-vanilloyl and tri-vanilloyl derivatives for use in anti-cancer therapy |
| 04/22/2010 | CA2735477A1 Unsymmetrical pyrrolobenzodiazepine-dimers for treatment of proliferative diseases |
| 04/21/2010 | EP2177620A1 Soluble hyaluronidase glycoprotein (sHASEGP), process for preparing the same, uses and pharmaceutical compositions comprising thereof |
| 04/21/2010 | EP2177619A1 HSV strains for the oncolytic treatment of cancer |
| 04/21/2010 | EP2177534A2 Heteroclitic analogs of class i epitopes |
| 04/21/2010 | EP2177530A1 Octapeptide having antiangiogenic activity |
| 04/21/2010 | EP2177525A1 Metal complex compound, cancer therapeutic composition comprising the metal complex compound as active ingredient, and intermediate for production of the metal complex compound |
| 04/21/2010 | EP2177510A1 Allosteric protein kinase modulators |
| 04/21/2010 | EP2177502A1 Compounds and their use |
| 04/21/2010 | EP2177231A2 Use of goat serum for veterinary treatment |
| 04/21/2010 | EP2177230A1 Immunoliposome inducing apoptosis into cell expressing death domain-containing receptor |
| 04/21/2010 | EP2177223A2 Homoharringonine alone or combined with other agents for use in treating chronic myelogenous leukemia resistant or intolerant to sti571 |
| 04/21/2010 | EP2177222A1 Pyrimidylaminobenzamide derivatives for the treatment of neurofibromatosis |
| 04/21/2010 | EP2177219A1 Preventive agent or therapeutic agent for disease caused by abnormal bone metabolism |
| 04/21/2010 | EP2177212A1 Methods of using lamellar bodies for therapeutic purposes |
| 04/21/2010 | EP2176665A1 Tumor cell-derived microvesicles |
| 04/21/2010 | EP2176406A1 Compositions and methods of treating cancer |
| 04/21/2010 | EP2176296A1 Anti-cd79b antibodies and immunoconjugates and methods of use |
| 04/21/2010 | EP2176295A1 Humanized anti-cd79b antibodies and immunoconjugates and methods of use |
| 04/21/2010 | EP2176260A1 Pyrazolo[1,5-a]pyridines and their use in cancer therapy |
| 04/21/2010 | EP2176259A1 Fused imidazoles for cancer treatment |
| 04/21/2010 | EP2176256A2 Trisubstituted pyrimidine derivatives for the treatment of proliferative diseases |
| 04/21/2010 | EP2176255A1 Andrographolide derivatives and use thereof in manufacture of medicaments |
| 04/21/2010 | EP2176254A1 Dna pk inhibitors |
| 04/21/2010 | EP2176250A1 Substituted heteroarylpiperidine derivatives as melanocortin-4 receptor modulators |
| 04/21/2010 | EP2176238A1 Morpholino pyrimidine derivatives used in diseases linked to mtor kinase and/or pi3k |
| 04/21/2010 | EP2176237A1 Phthalazinone derivatives as inhibitors of parp-1 |
| 04/21/2010 | EP2176236A1 6-thioxo-pyridazine derivatives |
| 04/21/2010 | EP2176231A1 Substituted indazole derivatives active as kinase inhibitors |
| 04/21/2010 | EP2175888A2 Polysaccharides grafted by polyamines for the preparation of radiopharmaceutical compositions |
| 04/21/2010 | EP2175879A1 Treatment of prion protein related diseases |
| 04/21/2010 | EP2175875A2 Compositions of prokaryotic phenylalanine ammonia-lyase and methods of treating cancer using compositions thereof |
| 04/21/2010 | EP1888584B1 1, 6 -dihydro- 1,3, 5, 6-tetraaza-as-indacene based tricyclic compounds and pharmaceutical compositions comprising same as inhibitors of ikk enzyme activity |
| 04/21/2010 | EP1819728B1 Il-7 variants with reduced immunogenicity |
| 04/21/2010 | EP1610780B1 Cyclic protein tyrosine kinase inhibitors |
| 04/21/2010 | EP1424960B1 Removable stent |
| 04/21/2010 | EP1272175B1 N,n'-diaryl guanidines as il-8 receptor antagonists |
| 04/21/2010 | EP1258252B1 Integrin expression inhibitors |
| 04/21/2010 | EP0910369B1 Benzothiophenes, formulations containing same, and methods |
| 04/21/2010 | EP0870033B1 Integrin-linked kinase, its inhibitors and methods of medical treatment using these inhibitors, gene therapy and pseudo-substrate inhibitors |
| 04/21/2010 | CN1935812B Metal fullerol and its pharmaceutical use for inhibiting tumour growth |
| 04/21/2010 | CN1795195B Pyridopyrazines and the use thereof as kinase inhibitors |
| 04/21/2010 | CN1740169B Arylmethylamine derivatives for use as tryptase inhibitors |
| 04/21/2010 | CN1689628B Medical purpose of creat extract |
| 04/21/2010 | CN101696413A SiRNA-935 capable of inhibiting BCLL11B expression and tumorous T cell proliferation and use thereof |
| 04/21/2010 | CN101696412A SiRNA-434 capable of inhibiting BCL11B expression and tumorous T cell proliferation and use thereof |
| 04/21/2010 | CN101696270A Hydrophilic polymer of resveratrol conjugate and preparing method thereof |
| 04/21/2010 | CN101696205A 3-(substituted xylylenimine-2-yl)-2,6-dioxopiperidine polymorph and pharmaceutical composition |
| 04/21/2010 | CN101696183A (Z)-2-phenyl-3-(pyrrol-2-yl)-acrylonitrile derivative as well as salts, composition, preparation method and application thereof |
| 04/21/2010 | CN101696166A Preparation method for danshen root salvianolic acid A |
| 04/21/2010 | CN101695574A Combination therapies for b-cell lymphomas comprising administration of anti-cd20 antibody |
| 04/21/2010 | CN101695561A Traditional Chinese medicinal composition for treating liver cancer |
| 04/21/2010 | CN101695546A Chinese medicament for treating alimentary tract cancer and preparation method thereof |
| 04/21/2010 | CN101695517A Starfish extract and application thereof in preparation of anti-tumor medicaments |
| 04/21/2010 | CN101695513A Composition with anti-tumor effect and application thereof |
| 04/21/2010 | CN101695502A Lanthanum fullerenol and application in preparing medicaments for inhibiting tumor growth |
| 04/21/2010 | CN101695501A Chitosan entrapment body of nano-scale arsenous acid and manufacturing method thereof |
| 04/21/2010 | CN101695479A Instant pirarubicin freeze-dried powder injection and preparation method thereof |
| 04/21/2010 | CN101695476A Method for preparing medical nanoparticles |
| 04/21/2010 | CN101695474A Pharmaceutical composition of vinflunine which is intended for parenteral administration preparation method thereof and use of same |
| 04/21/2010 | CN101695374A Composition comprising alkaline sphingomyelinase for use as a dietetic preparation, food supplement or pharmaceutical product |
| 04/21/2010 | CN101167755B Method for preparing centipede polysaccharide protein composition with anti-tumor activity and use |
| 04/21/2010 | CN101167719B Gallo catechin and gallate microcapsule granule and preparation technique thereof |
| 04/21/2010 | CN101156865B Antineoplastic new usage of cardiac glycoside compound in antiar |
| 04/21/2010 | CN101156639B Health-care anticancer tea and its preparing process |
| 04/21/2010 | CN101129436B Method of producing dandelion medicinal granules |
| 04/21/2010 | CN101062950B Polyethylene glycol modified thymus peptide 1 derivative |
| 04/21/2010 | CN101036637B Application of salvia miltiorrhiza bge I sodium sulfonate in the preparation of medicine |
| 04/21/2010 | CN101018846B Method for producing unsaturated fatty acid concentrate |
| 04/21/2010 | CN100998626B Method for preparing extract of korea thistle leaf |
| 04/20/2010 | USRE41253 Antineoplastic combinations |
| 04/20/2010 | USRE41252 Peptidyl prodrugs and linkers and stabilizers useful therefor |
| 04/20/2010 | US7700763 3-triazolyl-galactoside inhibitors of galectins |
| 04/20/2010 | US7700758 Preparing library of heterogenous small interfering RNA sequences (HSIRNA) for use in gene expression inhibition and mammalian therapeutics; gene therapy |